SCHRODINGER INC (SDGR)
Health Care · Computational Life Sciences / Drug Discovery Software · NASDAQ
Physics-based computational platform that accelerates drug discovery and materials science by predicting molecular properties with high accuracy, enabling faster, cheaper, and more successful drug development.
What SCHRODINGER INC does
Schrödinger operates a physics-based computational platform that enables faster, more cost-effective discovery of novel molecules for drug development and materials applications compared to traditional methods. The company generates revenue through two segments: software licensing to biopharmaceutical companies, industrial firms, academic institutions, and government laboratories; and drug discovery programs conducted both collaboratively with major pharma partners and through proprietary pipeline advancement. The software solutions accelerate all stages of molecular discovery, design, and optimization by predicting critical molecular properties with high accuracy, thereby reducing development timelines and failure rates.
Themes: Computational drug discovery / molecular property prediction, AI-driven small molecule design, Biopharmaceutical software platforms, Materials science / advanced materials discovery, Clinical-stage drug development / therapeutics
Fundamentals
- Price$19.71 as of 2026-08-21 close
- Market cap$1.4B as of 2026-08-24
- 1-year return+0.7% 2025-08-21 close $19.58 → 2026-08-21 close $19.71
- P/En/a negative earnings
- Net margin-21.0% as of 2026-08-24
- Gross margin+56.9% as of 2026-08-24
- ROE-16.4% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+8.9% as of 2026-08-24
- Revenue CAGR (3y)+12.2% SEC XBRL
- Beta1.69 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How SDGR compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How SCHRODINGER INC looks technically
SCHRODINGER INC (SDGR) is trading 29.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 12 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 70, in overbought territory (above 70). It made a new 20-day high about 3 trading days ago.
Trend
9
| Distance from the 200-day | it is trading 29.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +29.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $16.38 | $16.38 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $15.20 | $15.20 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 17.82. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 12 trading days ago — a "golden cross", a bullish long-term signal | 12 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 29.6% above | +29.6% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control | 30.6 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 70, in overbought territory (above 70) | 70.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($15.20 to $20.48) — its "stochastic" reading is 85 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 85.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $23.02 | $23.02 |
|---|---|---|
| From the 52-week high | it is 14.4% below its 52-week high (its highest price of the past year) | -14.4% |
| Above the 52-week low | it is 80.1% above its 52-week low (its lowest price of the past year) | +80.1% |
| Below the 52-week high | it is 14.4% below its highest point of the past year | 14.4% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $117.00 (set on 2021-02-22) | $117.00 |
| Given back of the 52-week move | over the past year its closes ranged ($11.07 to $22.52), and it has recovered well over two thirds of its fall from last year’s high — 75% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $18.15 to $18.51. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 75.5% |
| From the all-time high | it is 83.2% below its all-time high | -83.2% |
| Nearest price level | it is sitting right on a resistance level at $19.80 — a price it turned at twice since 2025-06-23, most recently on 2025-07-01. Since 2024-08-21 it has 9 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.4% |
| All-time low | its lowest closing price on record is $10.95 (set on 2026-03-27) | $10.95 |
| Above the all-time low | it is 80.1% above its all-time low | +80.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 94% of the past ~6 months) | 94th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.8807 between its high and its low — about 4.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.8807 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $13.98 and $20.60 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $13.98 – $17.29 – $20.60 |
| Typical daily range (% of price) | its price moves about 4.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.5% |
| Stretch from the 200-day average | it is trading 5.1 daily ranges above its 200-day average price (29.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.02× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 4.2% since the prior reading | +4.2% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.3% |
|---|---|---|
| Open gap | it gapped 2.6% above the previous close 2 sessions ago and has not traded back through the level it left behind at 17.67 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.5% |
| Gap filled | a 2.2% gap down opened on 2026-07-17 has been "filled" 25 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 25 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 28.2 percentage points (the stock gained 30.5% while the market gained 2.3%) | +28.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 45.9 percentage points (the stock gained 49.0% while the market gained 3.1%) | +45.9% |
| vs market, 6 months | over the past 6 months this stock beat the market by 59.9 percentage points (the stock gained 70.9% while the market gained 11.1%) | +59.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 19.8 percentage points (the stock gained 0.7% while the market gained 20.5%) | -19.8% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 22% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 7.3% of the share price. | +22.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 39% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $14.18 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +39.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $18.35 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +7.4% |
Price levels it has turned at before
SDGR last closed at $19.71 on 2026-08-21. Since 2024-08-21 it has turned at 9 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $19.80 | Resistance | 0.4% above the last close | turned there twice · 2025-06-23 to 2025-07-01 |
| $19.42 | Support | 1.5% below the last close | turned there five times · 2024-10-22 to 2026-08-11 |
| $20.37 | Resistance | 3.3% above the last close | turned there four times · 2024-12-05 to 2025-08-22 |
| $18.75 | Support | 4.9% below the last close | turned there three times · 2024-12-19 to 2025-10-14 |
| $18.26 | Support | 7.3% below the last close | turned there five times · 2024-10-11 to 2025-12-04 |
| $22.13 | Resistance | 12.3% above the last close | turned there four times · 2024-08-29 to 2025-10-02 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $17.82.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $17.82 and $18.15 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 2 trading days, since 2026-08-20.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Broke out to a new 20-day high · in a strong, established uptrend (ADX) | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.57 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$21.43 range $17.00 – $30.00; median $20.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SDGR
- Consensus EPS estimate-$0.52 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on collaborative drug discovery programs and potential for milestone failures","Significant operating losses and history of unprofitability","Risk of software adoption cycles and competition in computational chemistry"]
What changed in the latest 10-Q
AI-assisted comparison of SDGR's 10-Q filed 2026-05-05 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- New section 'Financial Overview; Software Revenue and Collaborations' heading added in 2026-05-05 filing
- Disclosure of Eli Lilly's planned acquisition of Ajax announced April 27, 2026, with up to $2.3 billion in cash consideration in 2026-05-05 filing
- Disclosure that SDGR held 5.8% equity position in Ajax as of December 31, 2025 in 2026-05-05 filing
- Addition of detailed explanation of two reportable segments (software and drug discovery) in 2026-05-05 filing
- Detailed description of software licensing model, calculation-based licensing, and cloud-based subscription delivery in 2026-05-05 filing
- Expanded description of collaboration agreement structure including upfront consideration, discovery/development/commercial/regulatory milestones, royalties, and option fees in 2026-05-05 filing
- Addition of Bristol-Myers Squibb collaboration disclosure stating exclusive worldwide agreement for oncology, neurology and immunology targets, with up to $482.0 million in milestone payments for one remaining neurology target in 2026-05-05 filing
- Removed:
- Entire 'Proprietary Drug Discovery Programs' section removed from 2026-05-05 filing, which in 2025-11-05 filing contained detailed clinical trial data for SGR-1505, SGR-3515, and SGR-2921
- Reworded:
- Addition of phrase 'We offer our customers a variety of software solutions that accelerate all stages of molecule discovery, design, and optimization.' in 2026-05-05 filing (this sentence does not appear in 2025-11-05 filing)
- Notes:
- The newer filing (2026-05-05) appears to be truncated and ends mid-sentence in the BMS collaboration paragraph, so full comparison of all content changes may not be possible
- The older filing (2025-11-05) includes extensive proprietary drug discovery program details that are absent from the newer filing excerpt provided, but this may be due to truncation rather than actual removal
Risk Factors
- Added:
- Added net loss figures for three months ended March 31, 2026 ($60.0 million) and 2025 ($59.8 million) in newer filing
- Added net loss figures for years ended December 31, 2025 ($103.3 million) in newer filing
- Added accumulated deficit figure as of March 31, 2026 ($688.8 million) in newer filing
- Added reference to 'complete our ongoing Phase 1 dose-escalation clinical trials for SGR-1505 and SGR-3515' in newer filing
- Added discussion of software business revenue expansion 'beyond the biopharmaceutical industry including for materials science applications' in newer filing's risk factor
- Added new paragraph in newer filing explaining revenue transition from on-premise to hosted software arrangements and expected near-term revenue decline
- Added statement that quarterly revenues decreased by 2% from Q1 2025 to Q1 2026 ($59.6 million to $58.6 million) in newer filing
- Added statement that annual revenues increased by 23% from 2024 to 2025 ($207.5 million to $255.9 million) in newer filing
- Removed:
- Removed net loss figures for three and nine months ended September 30, 2025 and 2024 from newer filing
- Removed net income figure for year ended December 31, 2023 ($40.7 million) from newer filing
- Removed accumulated deficit figure as of September 30, 2025 ($661.3 million) from newer filing
- Removed discussion of Nimbus Therapeutics distributions and Structure Therapeutics gains from newer filing
- Removed language 'We anticipate that our operating expenses will increase substantially in the foreseeable future' replaced with 'Our operating expenses may increase'
- Removed reference to hiring 'clinical, quality control, regulatory, chemical, manufacturing and control and other scientific personnel' from newer filing's expense list
- Removed reference to hiring 'additional scientific personnel' in newer filing (older version had more specific categories)
- Removed revenue example comparing nine months ended September 30, 2024 and 2025 from newer filing
- Reworded:
- Changed 'conduct preclinical studies and conduct clinical trials for any of our product candidates' (older) to 'conduct preclinical studies for any of our product candidates and complete our ongoing Phase 1 dose-escalation clinical trials for SGR-1505 and SGR-3515' (newer)
- Changed 'We anticipate that our operating expenses will increase substantially in the foreseeable future' (older) to 'Our operating expenses may increase' (newer)
- Changed language regarding future financial results expectations to reflect more recent period comparisons (March 31 vs September 30 data)
- Notes:
- The older filing appears truncated at the end of the revenue discussion paragraph, making complete comparison of that section difficult
- The newer filing is also truncated mid-sentence at the end of the provided text
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($13647) — 1 selling insider
- Last 180 days0 buys · 4 sells ($1M) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-16. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SDGR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding SDGR as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 14,263,120
- Reported value $162,029,042
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
SDGR had 11,009,809 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for SDGR because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 11,009,809
- Prior settlement (shares) 10,582,154
- Reported change 4.04%
- Days to cover (reported) 12.83
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Exscientia
- Atomwise
- BenevolentAI
- Benchling
- Valo Health
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Frequently asked questions
What does SCHRODINGER INC (SDGR) do?
Schrödinger operates a physics-based computational platform that enables faster, more cost-effective discovery of novel molecules for drug development and materials applications compared to traditional methods. The company generates revenue through two segments: software licensing to biopharmaceutical companies, industrial firms, academic institutions, and government laboratories;
What sector is SCHRODINGER INC (SDGR) in?
SCHRODINGER INC (SDGR) is classified in the Health Care sector. Its industry is Computational Life Sciences / Drug Discovery Software. It trades on NASDAQ.
Who are SCHRODINGER INC's (SDGR) competitors?
Notable peers of SCHRODINGER INC (SDGR) include Exscientia, Atomwise, BenevolentAI, Benchling and Valo Health. This peer set is informational only — not financial advice.
Is SCHRODINGER INC (SDGR) overbought or oversold right now?
SCHRODINGER INC (SDGR) is currently in overbought territory (its 14-day RSI is 70, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SDGR come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.